You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.
You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.